ArticleHuman vaccines & immunotherapeutics2024
Epidemiological characteristics of breakthrough mumps infection cases from 2019 to 2023 in Chongqing, China.
Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study.Human vaccines & immunotherapeutics · 2025Article
- Development and characterization of the genotype F attenuated mumps candidate strains.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high coverage of mumps-containing vaccine (MuCV) has effectively controlled the mumps incidence, while the prevention and control of breakthrough cases has become a prominent problem. To analyze the epidemiology of mumps breakthrough cases in Chongqing from 2019 to 2023, and provide scientific evidence for the prevention and control of mumps. The data of clinical and laboratory-confirmed mumps cases in Chongqing from 2019 to 2023 were exported from the China Information System for Disease Control and Prevention. The immunization history was screened and matched from the Chongqing Immunization Program Information System. Least-Significant Difference (LSD) and T-test were used for data analysis. There were 12,566 breakthrough cases in Chongqing, accounting for 61.09% of the total mumps cases reported. The most breakthrough infection occurred in the 3-9 years age group. In 2019 and 2020, the mean age of breakthrough cases with two doses was older than that with one dose (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.